Revenues (Tables)

3 Months Ended

Mar. 31, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

	Three months ended March 31,
	2018						2017
	US		ROW		Total		US		ROW		Total
Neulasta®	$	1,009	$	146	$	1,155	$	1,048	$	162	$	1,210
Enbrel®	1,050		55		1,105		1,118		63		1,181
Sensipar® / Mimpara®	409		88		497		337		84		421
Prolia®	320		174		494		279		146		425
Aranesp®	225		229		454		278		233		511
XGEVA®	332		113		445		298		104		402
EPOGEN®	244		—		244		270		—		270
Other products	558		391		949		467		312		779
Total product sales1	$	4,147	$	1,196	$	5,343	$	4,095	$	1,104	$	5,199
Other revenues					211						265
Total revenues2					$	5,554					$	5,464

⁽¹⁾ Total product sales includes $34 million related to hedging losses and $57 million related to hedging gains for the three months ended March 31, 2018 and 2017, respectively.

⁽²⁾ Prior-period amounts are not adjusted under the modified-retrospective method of adoption.